Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fehm

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM StudyP A Fasching, T Fehm, S Kellner, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2018
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM studyN Nabieva, T Fehm, L Häberle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patientsN Nabieva, S Kellner, T Fehm, et al.
Nature Medicine|June 6, 2023
The German Network for Personalized Medicine to enhance patient care and translational researchA L Illert, A Stenzinger, M Bitzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM StudyP A Fasching, T Fehm, S Kellner, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2018
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM studyN Nabieva, T Fehm, L Häberle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patientsN Nabieva, S Kellner, T Fehm, et al.
Nature Medicine|June 6, 2023
The German Network for Personalized Medicine to enhance patient care and translational researchA L Illert, A Stenzinger, M Bitzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 10